Astec Lifesciences Limited
Astec, a subsidiary of Godrej, is into the business of agrochemicals which are triazole fungicides and also entered into herbicide manufacturing since 2021. The Company is into manufacturing of agrochemical active ingredients (technical), bulk and fo...
Key Metrics
EPS
-23.95
Current ratio
1.00
Debt/Equity
1.37
Debt/EBITDA
-1877.33
Interest coverage ratio
-1.45
Operating Cashflow to total debt
0.02
Financials
Pros & Cons
Exclusive on TAP Bonds
Here's what we like about this company and potential risks we have identified.
Pros
Strong Linkages with Parent
Established Position in Triazole Fungicides; Product Addition and CDMO Key Growth Drivers
Strong Market Position of Parent in Animal Feed and Domestic Palm Oil
GAVL’s Healthy Diversification to Strengthen Consolidated Profitability
Robust Consolidated Credit Metrics
Liquidity: Adequate
Cons
Sharp Fall in Astec’s Performance in FY24; Modest Recovery likely in 2HFY25
Planned Capex to Keep Astec’s Leverage Elevated in Near Term
Stock is trading at 6.70 times its book value
Company has low interest coverage ratio.
The company has delivered a poor sales growth of 1.24% over past five years.
Company has a low return on equity of 5.97% over last 3 years.
Company might be capitalizing the interest cost
Disclaimer: Tap Bonds gathers data directly from the respective OBPP websites but does not guarantee its accuracy. We do not offer investment advice or endorse the purchase of any securities mentioned, nor do we warrant the reliability of the information collected.
About Astec Lifesciences Limited bond.
This comprehensive profile covers key factual information about ASTEC LIFESCIENCES LIMITED. Astec, a subsidiary of Godrej, is into the business of agrochemicals which are triazole fungicides and also entered into herbicide manufacturing since 2021. The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries. Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B). EPS in Mar-2024 was -23.95. Current ratio in Mar-2024 was 1.00. Debt/Equity in Mar-2024 was 1.37. Debt/EBITDA in Mar-2024 was -1877.33. Interest coverage ratio in Mar-2024 was -1.45. Operating Cashflow to total debt in Mar-2024 was 0.02. Total revenue for Mar-2025(E) was ₹571.60. Net income for Mar-2025(E) stood at ₹56.43. Total assets as of Mar-2024 were ₹974.92. Operating cash flow for Mar-2024 was ₹10.22. Peers and comparison entities consist of ASTEC LIFESCIENCES LIMITED, Fertilisers And Chemicals Travancore Limited, Coromandel International Limited, UPL Limited. As of Dec 2024, promoters hold N/A% while others hold N/A% of equity. Key strengths include: Strong Linkages with Parent; Established Position in Triazole Fungicides; Product Addition and CDMO Key Growth Drivers; Strong Market Position of Parent in Animal Feed and Domestic Palm Oil; GAVL’s Healthy Diversification to Strengthen Consolidated Profitability; Robust Consolidated Credit Metrics; Liquidity: Adequate; . Key risks include: Sharp Fall in Astec’s Performance in FY24; Modest Recovery likely in 2HFY25; Planned Capex to Keep Astec’s Leverage Elevated in Near Term; Stock is trading at 6.70 times its book value; Company has low interest coverage ratio.; The company has delivered a poor sales growth of 1.24% over past five years.; Company has a low return on equity of 5.97% over last 3 years.; Company might be capitalizing the interest cost. Leadership team details include Anjali Gupte (Independent Director), Anurag Roy (Director), Ashok V Hiremath (Non Executive Director), Balram Singh Yadav (Non Executive Director), Brahma Nand Vyas (Independent Director), Burjis Nadir Godrej (Non Executive Director), Nadir B Godrej (Chairman), Nandkumar Dhekne (Independent Director), R R Govindan (Independent Director), Tejashree Pradhan (Company Secretary & Compliance Officer). This detailed corporate overview is structured to provide a thorough understanding of all available data points, enhance search visibility, and support investor analysis.